Structural analysis reveals that novel methyltetrazole-containing WIN compounds bind differently in the VP1 pocket of human rhinovirus 14, potentially explaining differences in antiviral potency.
Answers are grounded in this paper and cite their sources.
These distinct VP1 binding modes may guide rhinovirus antiviral optimization; hypothesis-generating and should not yet change practice.
Four novel antiviral WIN compounds, that contain a methyl tetrazole ring as well as isoxazole, pyridazine or acetylfuran rings, have had their structures determined in human rhinovirus serotype 14 at 2.9 A resolution. These compounds bind in the VP1 hydrophobic pocket, but are shifted significantly towards the pocket pore when compared to previously examined WIN compounds. A putative water network at the pocket pore is positioned to hydrogen bond with these four WIN compounds, and this network can account for potency differences seen in structurally similar WIN compounds.
No takes yet. Share an insight, caveat, or question.
Giranda et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: